Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently received a Notice of Acceptance issued by the National Medical Products Administration for the marketing application of Edaravone Dexborneol Concentrated Solution for Injection (specification: 5ml: Edaravone 10mg and Dexborneol 2.5mg).
The drug is indicated for improving neurological symptoms, activities of daily living, and functional disabilities caused by acute ischemic stroke.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.